Who is sponsoring NCT04787471?

NCT04787471 is sponsored by Price Vision Group.

What drugs are being tested in NCT04787471?

Interventions in NCT04787471: 30 minute photoactivation of riboflavin 0.1%, 10 minute photoactivation of riboflavin 0.1%.

What condition does NCT04787471 study?

NCT04787471 studies Corneal Neovascularization.

Is NCT04787471 still recruiting?

NCT04787471 is currently recruiting now. Last updated 31 July 2025.

Last reviewed 2025-07-31 · How we verify

NCT04787471

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Corneal Crosslinking for Treatment of Corneal Neovascularization

Recruiting now Phase 2, PHASE3 Last updated 31 July 2025

What this trial tests

Phase 2, PHASE3 trial testing 30 minute photoactivation of riboflavin 0.1% in Corneal Neovascularization in 62 participants. Currently enrolling.

Timeline

3 May 2021

Primary endpoint
15 July 2026

15 September 2026

Quick facts

Lead sponsor	Price Vision Group
Phase	Phase 2, PHASE3
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	62
Start date	3 May 2021
Primary completion	15 July 2026
Estimated completion	15 September 2026
Sites	1 location across United States

Drugs / interventions tested

30 minute photoactivation of riboflavin 0.1%
10 minute photoactivation of riboflavin 0.1%

Conditions studied

Corneal Neovascularization — all drugs for Corneal Neovascularization →

Sponsor

Price Vision Group — full company profile →

Who can join

18 and older, any sex, with Corneal Neovascularization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study objective is to assess safety and efficacy of photo-activation of riboflavin for treatment of corneal neovascularization with or without concomitant inflammation and/or infection.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Price Vision Group trials

Trials by the same sponsor.

NCT05136443 — Loteprednol Etabonate 0.25% for Prevention of Cornea Transplant Rejection · Phase 4 · completed
NCT04141865 — Effect of Xen Implantation on the Aqueous Humor Proteome · terminated
NCT04051463 — Rhopressa for Corneal Edema Associated With Fuchs Dystrophy · Phase 2, PHASE3 · completed
NCT03971357 — Trial of Netarsudil for Acceleration of Corneal Endothelial Restoration · Phase 2, PHASE3 · terminated
NCT03922542 — Comparison of Standard vs. Accelerated Corneal Crosslinking · Phase 2, PHASE3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04787471 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Price Vision Group
Last refreshed: 31 July 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04787471.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing